Zydus Lifesciences Ltd

532321

Overview

    • Equity Style Box

      Large Blend

    • Sector

      Healthcare

    • Industry

      Drug Manufacturers - Specialty & Generic

    • Day Range

      885.70 – 905.80

    • Year Range

      859.15 – 1,323.90

    • Market Cap

      892.9824 Bil

    • Volume / Avg

      14.8 k / 44.9 k

    • Price / Sales

      4.22

    • Price / Book

      4.18

    • Price / Earnings

      20.16

    • Forward Div Yield

      0.33%

    • Trailing Div Yield

      0.33%

Login To Show Full Chart

Summary

Fair Value Assessment
Undervalued (5% Discount)
Fair ValueQ963.00UncertaintyMedium
Close Price907.00Mar 26, 2025
₹ 886.00
Price Down by 21.00 | 2.32 %
Trading Information Business Description
Previous Close
907.00
Day Range
885.70 – 905.80
Year Range
859.15 – 1,323.90
Bid / Ask
885.55 × 886.15
Market Cap
893.0 Bil
Volume / Average
14.8 k / 44.9 k
Beta (5-Year)
0.42
Shares Outstanding
1,006.23 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.
Contact
Scheme No. 63, Sarkhej-Gandhinagar Highway Zydus Corporate Park, Survey No. 536, Ahmedabad, GJ 382481
T +91 7971800000
www.zyduslife.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
29,475
As of Mar 31, 2024

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
216.50 190.22 168.78 148.28 148.22 138.12
Revenue Growth %
16.98% 12.70% 13.83% 4.97% 7.31% 8.34%
Gross Profit
151.25 125.21 103.19 90.09 93.42 86.63
Gross Profit Margin %
69.86% 65.83% 61.14% 60.76% 63.03% 62.72%
Operating Income
54.73 45.40 28.55 24.77 26.26 20.57
Operating Margin %
25.28% 23.87% 16.92% 16.70% 17.72% 14.89%
EBIT
58.62 47.26 26.40 28.84 23.95 17.87
EBIT Margin %
27.07% 24.85% 15.64% 19.45% 16.16% 12.93%
EBITDA
67.45 54.90 33.62 36.20 31.20 24.83
EBITDA Margin %
31.15% 28.86% 19.92% 24.41% 21.05% 17.98%
Net Income
45.37 38.60 19.60 44.87 21.34 11.77
Net Profit Margin %
21.58% 20.76% 12.42% 16.00% 14.74% 8.72%
Basic EPS
45.03 38.14 19.30 43.83 20.84 11.49
Diluted EPS
45.03 38.14 19.30 43.83 20.84 11.49
Normalized EPS
43.62 36.84 22.72 19.66 21.58 14.30
Total Dividends per Share
3.00 6.00 2.50 3.50 — 7.00
Balance Sheet (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
314.46 292.81 257.56 277.95 238.85 236.87
Total Liabilities
72.91 71.79 60.68 87.42 89.55 119.76
Total Debt
1.91 8.04 11.95 42.21 46.08 80.14
Total Equity
241.55 221.02 196.88 190.54 149.30 117.10
Cash And Cash Equivalents
10.61 4.13 4.88 6.58 6.65 8.45
Working Capital
68.06 61.60 44.86 44.22 8.55 4.46
Shares Outstanding (Bil)
— — 1.01 — 1.02 —
Book Value Per Share
— 197.07 173.05 166.05 126.91 101.35
Total Debt To Equity
0.01 0.04 0.06 0.22 0.31 0.68
Cash Flow Statement (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
45.94 32.28 26.89 21.04 32.93 25.05
Cash From Investing Activities
-27.48 -14.75 11.71 11.54 -7.23 -10.12
Cash From Financing Activities
-10.96 -18.10 -44.00 -8.68 -25.49 -10.94
Capital Expenditures
— 9.07 10.31 12.03 8.54 9.04
Free Cash Flow
— 31.20 17.68 11.42 20.61 14.72
Change in Cash
7.50 -0.58 -5.40 23.90 0.22 3.99

Profile

Name (Age)
5-Year Trend
2021
2022
2023
2024
2025
Sharvil Pankajbhai Patel (45) Director and Managing Director — — — — — —
Total Compensation for all Key Executives — — — — — —
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership


STOCKS
MUTUAL FUNDS
ADITYABIRLAAXISBajajBANDHANBARODABNPBOICANARADSPEDELWEISSFRANKLINTEMPLETONGROWWHDFCHELIOSHSBCICICIIIFLINVESCOITIJMKOTAKLICMahindraManulifeMIRAEMOTILALNAVINipponNJOldBridgePGIMPPFASQUANTQUANTUMSAMCOSBISHRIRAMSUNDARAMTATATAURUSTrustUNIONUTIWhiteOakZERODHA
INSURANCE FUNDS
ABSLAEGONAGEASFEDERALAVIVABAJAJALLIANZBHARTIAXACANARAHSBCORIENTBANKEDELWEISSTOKIOEXIDEFUTUREGENERALIHDFCICICIPRUDENTIALINDIAFIRSTKOTAKMAHINDRALICMAXLIFEPNBMETLIFEPRAMERICARELIANCENIPPONSAHARASBISHRIRAMSTARUNIONDAI-ICHITATAAIA

About Us

Connect With Us

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top